SCHEMBL1337620

SCHEMBL1337620

COc1ccc(Cl)c(-c2ccc(NC(=O)c3ccccc3C(=O)O)cc2F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
MAPT P10636 1/20 0.52
HPGD P15428 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
PRKAB2 O43741 1/20 0.50
PRKAG1 P54619 1/20 0.50
PRKAA2 P54646 1/20 0.50
PRKAA1 Q13131 1/20 0.50
PRKAG3 Q9UGI9 1/20 0.50
PRKAG2 Q9UGJ0 1/20 0.50
PRKAB1 Q9Y478 1/20 0.50
PARP1 P09874 1/20 0.50
PARG Q86W56 1/20 0.50
KMT2A Q03164 3/20 0.47
KDM4E B2RXH2 2/20 0.47
MEN1 O00255 2/20 0.47
ALDH1A1 P00352 1/20 0.47
GAA P10253 2/20 0.47
POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1337693 0.82 DHODH (0.50) NPC1RAB9AMAPTKMT2AKDM4E
SCHEMBL1336603 0.80 DHODH (0.46) NPC1RAB9AMAPTKMT2AKDM4E
SCHEMBL12189549 0.76 NPC1 (0.72) NPC1RAB9AMAPTKMT2AMEN1
SCHEMBL1335675 0.76 DHODH (0.46) NPC1RAB9AKMT2AKDM4EMEN1
SCHEMBL7824838 0.75 FADS1 (0.72) NPC1RAB9AMAPTHPGDSMN1; SMN2
SCHEMBL3209880 0.75 KDM4E (0.73) NPC1RAB9AMAPTHPGDSMN1; SMN2
SCHEMBL22113944 0.74 KMT2A (0.58) NPC1RAB9AMAPTHPGDSMN1; SMN2
SCHEMBL4600243 0.74 PRKAB2 (0.55) RAB9ASMN1; SMN2PRKAB2PRKAG1PRKAA2
SCHEMBL1337587 0.73 DHODH (0.53) NPC1RAB9AKMT2AKDM4EMEN1
SCHEMBL10489740 0.73 NPC1 (0.69) NPC1RAB9AMAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566847-B1 NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS ICOZEN THERAPEUTICS PVT LTD (IN) 2018-11-07 EP claimed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US claimed
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (CH) 2014-08-07 US claimed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 US claimed
EP-2566847-B1 NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS ICOZEN THERAPEUTICS PVT LTD (IN) 2018-11-07 EP disclosed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US disclosed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US disclosed
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (CH) 2014-08-07 US disclosed
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (CH) 2014-08-07 US disclosed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 US disclosed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR NPC1 1428/4885RAB9A 3073/4885MAPT 3142/4885
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR NPC1 1428/4885RAB9A 3073/4885MAPT 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.